<DOC>
	<DOCNO>NCT01953588</DOCNO>
	<brief_summary>The study conduct determine whether neoadjuvant endocrine therapy fulvestrant combination anastrozole fulvestrant , good anastrozole give surgery shrink cancer stop grow . Anastrozole inhibit tumor growth reduce level estrogen approve Food Drug Administration ( FDA ) United States use surgery postmenopausal woman estrogen receptor positive breast cancer . It also consider standard care give anastrozole month surgery shrink tumor . Fulvestrant inhibits tumor cell growth reduce level estrogen receptor tumor cell . It approve FDA use woman early stage breast cancer surgery , approve FDA patient advance ( Stage 4 ) estrogen receptor positive breast cancer spread part body .</brief_summary>
	<brief_title>Fulvestrant and/or Anastrozole Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery</brief_title>
	<detailed_description>This clinical trial design examine pathologic outcomes patient whose neoadjuvant treatment course determine use early marker endocrine resistance ( namely , Ki67 4 12 week neoadjuvant therapy ) well assess clinical outcome patient whose disease burden complete neoadjuvant endocrine therapy classify Modified PEPI 0 . The primary secondary objective study describe . Primary Objectives : 1 . To determine whether fulvestrant administer 24 week neoadjuvant endocrine treatment decrease proportion endocrine resistant tumors* relative patient treat anastrozole . 2 . To determine whether fulvestrant combination anastrozole , administer 24 week neoadjuvant endocrine treatment , decrease proportion endocrine resistant tumors* relative patient treat anastrozole . 3 . To assess whether 5 year RFS rate among woman modify preoperative endocrine prognostic index ( PEPI ) score 0 follow 24 week neoadjuvant anastrozole treatment least 95 % . 4 . To assess whether 5 year RFS rate among woman modify PEPI score 0 follow 24 week neoadjuvant fulvestrant , fulvestrant combination anastrozole , least 95 % . Note objective test select fulvestrant arm show superior anastrozole objective 1 2 . Endocrine resistant tumor define one follow criteria* : - Ki67 &gt; 10 % 4 week neoadjuvant endocrine therapy - Ki67 &gt; 10 % 12 week neoadjuvant endocrine therapy - Progressive disease document anytime neoadjuvant endocrine therapy - Surgical finding 22-24 week post neoadjuvant endocrine therapy : - pT stage 3/4 - positive lymph node present Ki67 &gt; 2.7 % ( ie modify PEPI score 0 ) - Discontinued neoadjuvant endocrine treatment reason Secondary Objectives : 1 . To assess whether 5 year RFS rate among woman preoperative endocrine prognostic index PEPI score 0 follow 24 week neoadjuvant anastrozole treatment least 95 % . 2 . To examine difference surgical outcome , clinical radiological response rate , safety profile fulvestrant arm anastrozole arm . 3 . To examine difference surgical outcome , clinical radiological response rate , safety profile patient randomize fulvestrant combination anastrozole randomized anastrozole . 4 . To examine rate pathologic complete response ( pCR ) 12 week neoadjuvant paclitaxel patient endocrine resistant disease follow 4 week 12 week neoadjuvant endocrine therapy ( either fulvestrant anastrozole combination fulvestrant anastrozole ) . 5 . To examine rate pathologic complete response ( pCR ) among patient endocrine resistant disease , follow 4 week 12 week neoadjuvant endocrine therapy ( either fulvestrant anastrozole combination fulvestrant anastrozole ) , choose receive neoadjuvant paclitaxel , another standard neoadjuvant taxane and/or anthracycline contain regimen CMF . 6 . To summarize frequency severe ( NCI CTCAE grade &gt; 3 ) adverse event encounter administration paclitaxel neoadjuvant setting . 7 . To assess RFS patient endocrine resistant tumor define : 1 ) Ki67 &gt; 10 % week 4 , 2 ) Ki67 &gt; 10 % week 12 3 ) modify PEPI score non-zero neoadjuvant endocrine therapy , three group combine separate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Female ≥18 year age 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 3 . Postmenopausal , verify : post bilateral surgical oophorectomy spontaneous menses ≥ 1 year menses &lt; 1 year folliclestimulating hormone ( FSH ) estradiol level postmenopausal range , accord institutional standard 4 . Pathologic confirmation invasive breast cancer diagnose core needle biopsy 5 . Clinical T2T4c , N , M0 invasive breast cancer , AJCC 7th edition clinical staging , goal surgery complete excision tumor breast lymph node . Primary tumor must : palpable large diameter least 2.0 cm physical examination radiological assessment Note : Patients contralateral ductal carcinoma situ and/or invasive breast cancer eligible . Patients multicentric breast cancer ( define one lesion invasive breast cancer breast separate ≥ 2 cm normal breast tissue eligible . 6 . Invasive breast cancer estrogen receptor positive Allred score 6 , 7 8 local institution standard protocol . If Allred Score report diagnostic pathology report , ER positivity &gt; 66 % cell eligible . If ER positivity ≤ 66 % , stain intensity ( weak , intermediate , strong ) need calculate Allred Score determine eligibility . 7 . Invasive breast cancer Human Epidermal Growth Factor Receptor 2 ( HER2 ) A patient consider HER2 negative breast cancer one follow applies : 0 1+ immunohistochemistry ( IHC ) ISH do 0 1+ IHC ISH ratio ( HER2 gene copy/chromosome 17 ) &lt; 2 2+ IHC ISH ratio ( HER2 gene copy/chromosome 17 ) &lt; 2 8 . Documentation mammogram ultrasound ( include ductal carcinoma situ ( DCIS ) invasive cancer ) diseased breast perform within 56 day prior registration . Mammogram unaffected contralateral breast require within 12 month prior registration . 9 . Laboratory value ( ≤ 14 day prior registration ) : 1 . Absolute Neutrophil Count ( ANC ) &gt; 1000/mm^3 2 . Platelet Count &gt; 100,000/mm^3 3 . Total Bilirubin &lt; 1.5 x upper limit normal ( ULN ) 4 . Creatinine &lt; 1.5 x ULN 5 . Serum alanine transaminase ( ALT ) &lt; 2.5 x ULN 10 . Tissue acquisition : Patient must agree provide require research biopsy baseline , week 4 surgery integral integrate biomarker correlative study . 1 . Premenopausal status 2 . Inflammatory breast cancer define clinically significant erythema breast and/or document dermal lymphatic invasion ( direct skin invasion tumor peau ' orange without erythema ) . 3 . An excisional biopsy breast cancer . 4 . Hormone replacement therapy type , megestrol acetate , raloxifene within one week prior registration . 5 . Tumor estrogen receptor ( ER ) Allred score 05 HER2 positive IHC ( 3+ ) amplify FISH &gt; 2.0 . 6 . Surgical axillary staging procedure prior study entry . Note : Fine needle aspiration ( FNA ) core needle biopsy axillary node permit . 7 . Clinical radiographic evidence metastatic disease . Metastatic workup require , recommend patient clinical stage III disease . Note : Isolated ipsilateral supraclavicular node involvement permit . 8 . Breast implant contraindicate implant precludes require research biopsy interfere palpate breast lesion . 9 . Treatment cancer include surgery , radiation therapy , chemotherapy , biotherapy , hormonal therapy investigational agent prior study entry . 10 . History invasive breast cancer contralateral DCIS .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>